Table 1.
Clinical characteristics of enrolled patients
| Patient characteristics | Training cohort (n = 100) |
Validation cohort (n = 52) |
P * |
|---|---|---|---|
| Age (mean ± SD) (years) | 57.8 ± 14.6 | 59.4 ± 15.7 | 0.533 |
| Gender | 0.494 | ||
| Male | 48 | 28 | |
| Female | 52 | 24 | |
| LDH | 0.586 | ||
| Normal | 45 | 21 | |
| Elevated | 55 | 31 | |
| β2-MG | 0.367 | ||
| Normal | 67 | 31 | |
| Elevated | 33 | 21 | |
| Ann Arbor stage | 0.261 | ||
| I–II | 38 | 15 | |
| III–IV | 62 | 37 | |
| Performance status | 0.062 | ||
| < 2 | 76 | 32 | |
| ≥ 2 | 24 | 20 | |
| Extranodal sites | 0.099 | ||
| < 2 | 71 | 30 | |
| ≥ 2 | 29 | 22 | |
| B symptoms | 0.188 | ||
| Yes | 28 | 20 | |
| No | 72 | 32 | |
| IPI score | 0.664 | ||
| ≤ 2 | 54 | 30 | |
| > 2 | 46 | 22 | |
| Cell of origin | 0.888 | ||
| GCB | 28 | 14 | |
| Non-GCB | 72 | 38 | |
| Treatment | 0.729 | ||
| Chemotherapy alone | 72 | 41 | |
| Chemotherapy + ISRT | 25 | 10 | |
| Chemotherapy + ASCT | 3 | 1 | |
| Chemotherapy regimens | |||
| R-CHOP | 95 | 48 | 0.760 |
| R-EPOCH | 5 | 4 | |
| Endpoint | |||
| 2-year PFS rate (%) | 75.0 | 71.2 | 0.271 |
| 2-year OS rate (%) | 80.0 | 76.9 | 0.352 |
LDH lactate dehydrogenase, β2-MG β2-microglobulin, IPI International Prognostic Index, GCB germinal center B-cell like, ISRT involved-site radiotherapy, ASCT autologous stem cell transplantation, PFS progression-free survival, OS overall survival
*P value was calculated by independent t-test for continuous variables, chi-square test for categorical variables, and log-rank test for survival rates